Literature DB >> 12947141

Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

T L Pitt1, M Sparrow, M Warner, M Stefanidou.   

Abstract

BACKGROUND: Respiratory infection with Pseudomonas aeruginosa is very common in patients with cystic fibrosis (CF) but antimicrobial resistance rates of CF isolates across the UK are largely unknown.
METHODS: The susceptibility of 417 CF patient isolates of P aeruginosa from 17 hospitals to six commonly prescribed antibiotics were examined. Isolates were tested by an agar break point dilution method and E-tests according to British Society of Antimicrobial Chemotherapy guidelines. Genotyping of isolates was performed by XbaI DNA macrorestriction and pulsed field gel electrophoresis.
RESULTS: 38% of isolates were susceptible to all of the agents tested; almost half were resistant to gentamicin compared with ceftazidime (39%), piperacillin (32%), ciprofloxacin (30%), tobramycin (10%), and colistin (3%). Approximately 40% were resistant to two or more compounds with ceftazidime in combination with gentamicin, piperacillin or ciprofloxacin being the most common cross resistances. Resistance rates were generally similar to those reported recently from the USA and Germany. A selection of resistant isolates proved to be predominantly genotypically distinct by XbaI DNA macrorestriction but six pairs from three centres had similar genotypes.
CONCLUSIONS: The level of resistance to front line antipseudomonal agents, with the exception of colistin, is disturbingly high. The prudent use of antimicrobial drugs and closer monitoring of accumulation of resistant strain populations should be actively considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947141      PMCID: PMC1746803          DOI: 10.1136/thorax.58.9.794

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  18 in total

1.  In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.

Authors:  Tanja Schülin
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

2.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

3.  PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance.

Authors:  J S Gunn; K B Lim; J Krueger; K Kim; L Guo; M Hackett; S I Miller
Journal:  Mol Microbiol       Date:  1998-03       Impact factor: 3.501

4.  Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology.

Authors:  G Taccetti; S Campana; L Marianelli
Journal:  Eur J Epidemiol       Date:  1999-01       Impact factor: 8.082

Review 5.  Rational parameters for antibiotic therapy in patients with cystic fibrosis.

Authors:  J R Govan; C Doherty; S Glass
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

6.  Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  E F Marley; C Mohla; J M Campos
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

7.  Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.

Authors:  G L Morlin; D L Hedges; A L Smith; J L Burns
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

8.  Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.

Authors:  O Ciofu; B Giwercman; S S Pedersen; N Høiby
Journal:  APMIS       Date:  1994-09       Impact factor: 3.205

9.  Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients.

Authors:  J M Wolter; G Kotsiou; J G McCormack
Journal:  J Med Microbiol       Date:  1995-03       Impact factor: 2.472

10.  National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa.

Authors:  H Y Chen; M Yuan; I B Ibrahim-Elmagboul; D M Livermore
Journal:  J Antimicrob Chemother       Date:  1995-04       Impact factor: 5.790

View more
  42 in total

1.  Minimizing the toxicity of aminoglycosides in cystic fibrosis.

Authors:  Alan R Smyth
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

Review 2.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Genetic analysis of colistin resistance in Salmonella enterica serovar Typhimurium.

Authors:  Song Sun; Aurel Negrea; Mikael Rhen; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

Review 6.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

7.  Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Authors:  Berthony Deslouches; Kazi Islam; Jodi K Craigo; Shruti M Paranjape; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.

Authors:  J B Bulitta; S B Duffull; M Kinzig-Schippers; U Holzgrabe; U Stephan; G L Drusano; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

10.  Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.

Authors:  Xuan Qin; Danielle M Zerr; Michael A McNutt; Jessica E Berry; Jane L Burns; Raj P Kapur
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.